Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 184

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 184
---
 25 |

| Moore Financial Consulting |

| SKNY Pharmaceuticals, Inc. | April 2025   |
| Valuation                  | Page 6 of 25 |

The Company

SKNY Pharmaceuticals, Inc. (“SKNY”, or the “Company”) was founded in the United States as a private company.

The company’s field of activity is oral therapy; it developed a synthetic cannabinoid analog of THCV with unique receptor-interacting properties, SKNY-1 (hereinafter: “SKNY-1”, “analog”). The analog’s properties allow it to be effective in treating Nicotine dependence, smoking cessation, and weight loss.

Studies show that SKNY-1 can improve efficacy with a benight safety profile that will be attractive in the Nicotine dependence, Smoking cessation, and Weight loss markets.

SKNY-1 serves as a CB1 blocker, CB2 activator, and MOA inhibitor and stops the reward sensation in smokers. Nicotine withdrawal effects are common with OTC medications for Nicotine dependence; by avoiding these effects, SKNY-1 provides a more efficient therapeutic option.

Furthermore, SKNY1 is assumed to restore insulin sensitivity, decrease appetite, increase satiety, and up-regulate energy metabolism without safety issues.

According to the company, SKNY-1 is designed to offer superior efficacy to other oral anti-obesity medications while improving safety and tolerability, addressing key concerns, and improving compliance.

License agreement

MIRALOGX, LLC (hereinafter “Miralogx”) is a biotechnology company developing innovative, patented molecules to develop novel drugs for various healthcare solutions through exclusive licensing and strategic partnerships.

The company and Miralogx entered into a license agreement for SKNY-1. The agreement clarifies that the licensor (Miralogx) is the owner of the intellectual property. In addition, SKNY agrees to pay Miralogx 8.0% of all revenues (Net sales Price), excluding any commercial sales accounted for in the Net Sales Price, with a minimum annual payment of $250,000$. SKNY license is for the North American Territories (US, Canada and Mexico).

To the extent SKNY grants a sublicense to any third party and receives revenue, SKNY agrees to pay Miralogx 8.0% of the revenue received in the aggregate by the Licensee from all such sublicensees. SKNY will owe at most 8.0% of all consideration collectively received from all commercial sales and all third parties, excluding commercial sales.

The